Improving the osteogenic potential of BMP-2 with hyaluronic acid hydrogel modified with integrin-specific fibronectin fragment

Biomaterials

Volumn 34, Issue 3, 2013, Pages 704-712

  Kisiel, Marta ^a   Martino, Mikaël M ^b   Ventura, Manuela ^c   Hubbell, Jeffrey A ^b   Hilborn, Jöns ^a   Ossipov, Dmitri A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b EPFL   (Switzerland)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone regeneration; Cell adhesion; Fibronectin; Hyaluronic acid hydrogel; Integrins; RhBMP 2

Indexed keywords

BONE REGENERATION; FIBRONECTIN; HYALURONIC ACID HYDROGELS; INTEGRINS; RHBMP-2;

BONE; CELL ADHESION; CELL CULTURE; ORGANIC ACIDS; SCAFFOLDS (BIOLOGY);

HYDROGELS;

COLLAGEN FIBER; FIBRONECTIN; HYALURONIC ACID; INTEGRIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE REMODELING; CELL ADHESION; CELL SPREADING; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; HYDROGEL; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 2; CELL ADHESION; CELL LINE; DRUG CARRIERS; ELASTIC MODULUS; FIBRONECTINS; HUMANS; HYALURONIC ACID; HYDROGEL; INTEGRINS; MESENCHYMAL STROMAL CELLS; MICE; OSTEOGENESIS; RATS;

RATTUS;

EID: 84868463422     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.10.015     Document Type: Article

References (50)

1. Garrison K.R., Donell S., Ryder J., Shemilt I., Mugford M., Harvey I., et al. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol Assess 2007, 11:1-150. iii-iv.
2. Axelrad T.W., Einhorn T.A. Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev 2009, 20:481-488.
3. Kitamura M., Nakashima K., Kowashi Y., Fujii T., Shimauchi H., Sasano T., et al. Periodontal tissue regeneration using fibroblast growth factor-2: randomized controlled phase II clinical trial. PLoS ONE 2008, 3.
4. Frieden I.J. Addendum: commentary on becaplermin gel (Regranex) for hemangiomas. Pediatr Dermatol 2008, 25:590.
5. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011, 11:471-491.
6. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219.
7. Yamada K.M., Even-Ram S. Integrin regulation of growth factor receptors. Nat Cell Biol 2002, 4:E75-E76.
8. Giancotti F.G., Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 2003, 19:173-206.
9. Lin F., Ren X.D., Pan Z., Macri L., Zong W.X., Tonnesen M.G., et al. Fibronectin growth factor-binding domains are required for fibroblast survival. J Invest Dermatol 2011, 131:84-98.
10. Wijelath E.S., Rahman S., Namekata M., Murray J., Nishimura T., Mostafavi-Pour Z., et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 2006, 99:853-860.
11. Martino M.M., Tortelli F., Mochizuki M., Traub S., Ben-David D., Kuhn G.A., et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med 2011, 3:100ra89.
12. Menzel E.J., Farr C. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett 1998, 131:3-11.
13. Collis L., Hall C., Lange L., Ziebell M., Prestwich R., Turley E.A. Rapid hyaluronan uptake is associated with enhanced motility: implications for an intracellular mode of action. FEBS Lett 1998, 440:444-449.
14. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528-539.
15. Fraser J.R., Laurent T.C., Laurent U.B. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997, 242:27-33.
16. Prestwich G.D. Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine. J Control Release 2011, 155:193-199.
17. Burdick J.A., Prestwich G.D. Hyaluronic acid hydrogels for biomedical applications. Adv Mater 2011, 23:H41-H56.
18. Aro H.T., Govender S., Patel A.D., Hernigou P., Perera de Gregorio A., Popescu G.I., et al. Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Jt Surg Am 2011, 93:801-808.
19. Swiontkowski M.F., Aro H.T., Donell S., Esterhai J.L., Goulet J., Jones A., et al. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Jt Surg Am 2006, 88:1258-1265.
20. Bergman K., Engstrand T., Hilborn J., Ossipov D., Piskounova S., Bowden T. Injectable cell-free template for bone-tissue formation. J Biomed Mater Res A 2009, 91:1111-1118.
21. Martinez-Sanz E., Ossipov D.A., Hilborn J., Larsson S., Jonsson K.B., Varghese O.P. Bone reservoir: injectable hyaluronic acid hydrogel for minimal invasive bone augmentation. J Control Release 2011, 152:232-240.
22. Docherty-Skogh A.C., Bergman K., Waern M.J., Ekman S., Hultenby K., Ossipov D., et al. Bone morphogenetic protein-2 delivered by hyaluronan-based hydrogel induces massive bone formation and healing of cranial defects in minipigs. Plast Reconstr Surg 2010, 125:1383-1392.
23. Turley E.A., Noble P.W., Bourguignon L.Y. Signaling properties of hyaluronan receptors. J Biol Chem 2002, 277:4589-4592.
24. McCourt P.A., Ek B., Forsberg N., Gustafson S. Intercellular adhesion molecule-1 is a cell surface receptor for hyaluronan. J Biol Chem 1994, 269:30081-30084.
25. Ghosh K., Ren X.D., Shu X.Z., Prestwich G.D., Clark R.A. Fibronectin functional domains coupled to hyaluronan stimulate adult human dermal fibroblast responses critical for wound healing. Tissue Eng 2006, 12:601-613.
26. Shu X.Z., Ghosh K., Liu Y., Palumbo F.S., Luo Y., Clark R.A., et al. Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mater Res A 2004, 68:365-375.
27. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J Cell Sci 2006, 119:3901-3903.
28. Pfaff M., Tangemann K., Muller B., Gurrath M., Muller G., Kessler H., et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem 1994, 269:20233-20238.
29. Serini G., Valdembri D., Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006, 312:651-658.
30. Hamidouche Z., Fromigue O., Ringe J., Haupl T., Vaudin P., Srouji S., et al. Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Bone 2009, 44:S218-S219.
31. Petrie T.A., Raynor J.E., Reyes C.D., Burns K.L., Collard D.M., Garcia A.J. The effect of integrin-specific bioactive coatings on tissue healing and implant osseointegration. Biomaterials 2008, 29:2849-2857.
32. van der Walle C.F., Altroff H., Mardon H.J. Novel mutant human fibronectin FIII9-10 domain pair with increased conformational stability and biological activity. Protein Eng 2002, 15:1021-1024.
33. Martino M.M., Mochizuki M., Rothenfluh D.A., Rempel S.A., Hubbell J.A., Barker T.H. Controlling integrin specificity and stem cell differentiation in 2D and 3D environments through regulation of fibronectin domain stability. Biomaterials 2009, 30:1089-1097.
34. Kisiel M., Ventura M., Oommen O.P., George A., Walboomers X.F., Hilborn J., et al. Critical assessment of rhBMP-2 mediated bone induction: an in vitro and in vivo evaluation. J Control Release 2012, 162:646-653.
35. Martinez-Sanz E., Varghese O.P., Kisiel M., Engstrand T., Reich K.M., Bohner M., et al. Minimally invasive mandibular bone augmentation using injectable hydrogels. J Tissue Eng Regen Med 2012.
36. Ossipov D.A., Yang X., Varghese O., Kootala S., Hilborn J. Modular approach to functional hyaluronic acid hydrogels using orthogonal chemical reactions. Chem Commun 2010, 46:8368-8370.
37. Ossipov D.A., Piskounova S., Varghese O.P., Hilborn J. Functionalization of hyaluronic acid with chemoselective groups via a disulfide-based protection strategy for in situ formation of mechanically stable hydrogels. Biomacromolecules 2010, 11:2247-2254.
38. Yang X., Kootala S., Hilborn J., Ossipov D.A. Preparation of hyaluronic acid nanoparticles via hydrophobic association assisted chemical cross-linking - an orthogonal modular approach. Soft Matter 2011, 7:7517-7525.
39. Mantovani G., Lecolley F., Tao L., Haddleton D.M., Clerx J., Cornelissen J.J., et al. Design and synthesis of N-maleimido-functionalized hydrophilic polymers via copper-mediated living radical polymerization: a suitable alternative to PEGylation chemistry. J Am Chem Soc 2005, 127:2966-2973.
40. Wong L., Boyer C., Jia Z., Zareie H.M., Davis T.P., Bulmus V. Synthesis of versatile thiol-reactive polymer scaffolds via RAFT polymerization. Biomacromolecules 2008, 9:1934-1944.
41. Keselowsky B.G., Garcia A.J. Quantitative methods for analysis of integrin binding and focal adhesion formation on biomaterial surfaces. Biomaterials 2005, 26:413-418.
42. Kowalczynska H.M., Nowak-Wyrzykowska M., Dobkowski J., Kolos R., Kaminski J., Makowska-Cynka A., et al. Adsorption characteristics of human plasma fibronectin in relationship to cell adhesion. J Biomed Mater Res 2002, 61:260-269.
43. Nombela-Arrieta C., Ritz J., Silberstein L.E. The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol 2011, 12:126-131.
44. Marsell R., Einhorn T.A. The biology of fracture healing. Injury 2011, 42:551-555.
45. Docheva D., Popov C., Mutschler W., Schieker M. Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J Cell Mol Med 2007, 11:21-38.
46. Shapiro F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 2008, 15:53-76.
47. Fredriksson S., Gullberg M., Jarvius J., Olsson C., Pietras K., Gustafsdottir S.M., et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002, 20:473-477.
48. Soderberg O., Leuchowius K.J., Gullberg M., Jarvius M., Weibrecht I., Larsson L.G., et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 2008, 45:227-232.
49. Loy D.N., Crawford C.H., Darnall J.B., Burke D.A., Onifer S.M., Whittemore S.R. Temporal progression of angiogenesis and basal lamina deposition after contusive spinal cord injury in the adult rat. J Comp Neurol 2002, 445:308-324.
50. Martino M.M., Hubbell J.A. The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J 2010, 24:4711-4721.